Pharmacotherapy for multidrug resistant tuberculosis
- 1*,
- 1,
- 2,
- 1
- 1Departments of Pharmacology, College, Ajmer, Rajasthan, India Educational Forum.
- 2Respiratory Medicine, J. L. N. Medical College, Ajmer, Rajasthan, India Educational Forum.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Naveen Chhabra
Departments of Pharmacology, College, Ajmer, Rajasthan, India Educational Forum.
Copyright: © 2012 The Author(s). This is an open access article.
Abstract
The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs namely, isoniazid and rifampicin. Emergence of multidrug resistance tuberculosis (MDR- TB) is now a health problem faced by most of the developing countries as well as developed countries across the globe. MDR-TB is a man-made disease that is caused by improper treatment, inadequate drug supplies, and poor patient supervision. HIV infection and AIDS have been implicated as important cause for this. The review of a published literature suggests that the most powerful predictor of treatment of MDR-TB is a history of treatment of TB. Although the treatment is efficacious, there are also a number of adverse effects caused by drugs used in the treatment of MDR-TB.
Keywords
Subject
Recommended articles
- Ethionamide-induced gynecomastia
Ramakant Dixit, Jacob George, Arun K. Sharma · Journal of Pharmacology and Pharmacotherapeutics
Readers Also Viewed
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Exploring Interleukin-6 Inhibitor Antibodies in Combatting SARS-CoV-2 and its Mutated Variants: Challenges and Future Directions
Mohammed Ali Bakkari, Gassem Ghoal, Fahad Y. Sabei
Jan 1, 2025
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026